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ABSTRACT
BACKROUND AND OBJECTIVE
Cirrhosis is a common disease which has significant morbidity and it is one of
the cause for premature mortality. The major complication of cirrhosis is portal
hypertension which in turn leads to variceal bleeding which accounts for 35-
40% mortality.
In patients with chronic liver disease, endoscopic screening for esophageal
varices (EV) is currently recommended in all patients at the time of diagnosis of
cirrhosis. In order to improve the compliance of patients and to reduce the
burden on physicians and hospitals, invasive procedures to diagnose the
incidence of oesophageal varices need to be avoided and replaced with simple
and easily available and reproducible investigation/screening.
This study is done to analyse the predictive value in the diagnosis of
Oesophageal varices in patient with Cirrhosis with a non-invasive parameter
like Platelet count Splenic Diameter ratio.
METHODS
The study included 75 patients admitted in Government Rajaji Hospital,
Madurai with Cirrhosis in the period between September 2013 to August 2014.
Cirrhosis was diagnosed with the help of history, clinical examination and
ultrasonogram. All 75 patients underwent Ultrasonogram (for splenic diameter)
and platelet count was done. The following patients were included viz…1.Age
> 18 years/ Males 2.Patients undergoing screening endoscopy for varices at the
time of diagnosis of cirrhosis 3.Known cirrhotic patients who have never
undergone screening endoscopy for EV.Patients with
1.Active upper G.I.bleeding
2.Previous history of endoscopic sclerosis / band ligation of EV
3.Previous surgery for portal hypertension (stents)
4.Previous history of Beta Blocker treatment / prophylaxis.
5.Inabilty to abstain from alcoholism were excluded from the study.
The data and variables collected from the patients were compiled and analysed
with statistical methods (Chi square).
RESULTS AND INTERPRETATION
Among the 75 patients, a total of 50 patients had esophageal varices on upper
gastrointestinal endoscopy. Out of these, 48 patients had a platelet count/splenic
diameter <909. The remaining 2 patients had a ratio of >909.
A total of 54 patients in the study had a ratio of <909 in the study. Varices were
absent in 4 of them. The mean platelet count spleen diameter ratio of patients
with out varices was 961.98 and the mean platelet count spleen diameter ratio of
patients with varices was 689.62. Hence, using a ratio of 909 as cutoff, 96% of
patients with varices were detected (sensitivity-96% and specificity-90.48%).
The P value <o.oo7 which is more significant than using a single parameter.
The positive predictive value is 88.% and the negative predictive value is
90.4%.
CONCLUSION
Lower the platelet count spleen size ratio, higher the incidence of varices and
higher the grades. This study conclude that presence of a lower PC/SD ratio
determine the presence of varices and hence identify the subset of patients who
require endoscopy for the prophylactic management of esophageal varices.
Apart from being noninvasive, platelet count, spleen bipolar diameter and the
PC/SD ratio is a relatively inexpensive test.
KEY WORDS
Cirrhosis, oesophageal varices, platelet count-spleen diameter ratio,Upper
Gastrointestinal bleeding
INTRODUCTION 
                    Cirrhosis is a common disease which has significant 
morbidity and it is one of the cause for premature mortality. It can occur 
at any age. World-wide  the most common causes are viral hepatitis and 
consumption of excessive alcohol. 
                Among the viral hepatitis the most common are hepatitis B and 
C viruses. 300 million people are affected by viral hepatitis B. The 
spectrum is from acute infection mostly asymptomatic to a chronic 
hepatitis B which leads to complications such as cirrhosis and 
hepatocellular carcinoma. Following exposure to hepatitis B 15-20% 
develop cirrhosis  over 5-20years. The incidence of cirrhosis is directly 
proportional to the positivity of HBeAg. The patients infected with 
Hepatitis C  are unaware of the disease and diagnosed only when they 
progress to chronic liver disease.> 3/4th of  patients succumb to chronic 
infection and later leads to inadequate clearance of virus. 
             The next most common cause is chronic liver disease is Alcohol. 
The death due to alcoholic liver disease is on raising trend with over 
3000deaths/year. The mean age at presentation is also falling. When the 
alcohol consumption is > 160g/day for 8 years they are more to develop 
cirrhosis. 
1 
 
                  The 3rd most common cause of chronic liver disease is Non-
alcoholic fatty liver disease (NAFLD). It mostly affects the affluent 
societies. The prevalence increases with raise of obesity. The patients 
with Diabetes and Metabolic syndrome are more prone to develop 
NASH. 
                    The major complication of cirrhosis is portal hypertension 
which in turn leads to variceal bleeding which accounts for 35-40% 
mortality. 
                    In patients with chronic liver disease, endoscopic screening 
for esophageal varices (EV) is currently recommended in all patients  at 
the time of diagnosis of cirrhosis. As far as patients with no varices at 
screening endoscopy are concerned, surveillance should be performed 
every 2 years on patients with stable liver function and every year on 
those who show signs of liver function deterioration.  
                      Finally, endoscopy should be repeated every year when 
screening endoscopy reveals small varices. These practices are 
recommended because if high-risk EV are detected, then either 
pharmacologic or endoscopic treatment aimed at preventing first bleeding 
can be started                                                                                               .           
.                      Nevertheless, although criteria for this surveillance practice 
are part of well-established guidelines, they stem from the opinions of 
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experts rather than being evidence based. Furthermore, such policy 
eventually places a strong burden on medical resources, and may be 
hampered by the lack of compliance with both screening and 
surveillance. Indeed, one recent study compared universal endoscopic 
screening and treatment of high-risk varices with treating all cirrhotic 
patients with β-blockers, and the latter approach proved to be more cost-
effective. In another similar study, screening endoscopy proved to be 
cost-effective in patients with decompensated disease alone. Lastly, 
although administering  timolol to cirrhotic patients without EV proved to 
be ineffective at preventing the formation of varices and propranolol 
seemed to be ineffective in the prevention of the development of large 
varices.  
                Taking into account the above mentioned considerations, the 
cost- effectiveness of universal empirical β-blocker treatment should be 
even greater,  although in some patients it would be useless. In fact, the 
average prevalence of EV in cirrhotic patients ranges from 60% to 80%, 
depending on severity and etiology of liver disease, and empirical 
treatment of all cirrhotic patients would  expose a significant proportion 
of treated patients to unnecessary and potentially harmful side effects.       
               Therefore, the use of accurate and specific methods that  could 
noninvasively diagnose EV would likely increase the cost-benefit of  
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empirical treatment by decreasing the number of patients who are 
administered avoidable treatment and by increasing the number of 
properly screened and  treated patients. Such a noninvasive means should 
have a confident safety profile (i.e., a negative predictive value 
approaching 100%) so as to avoid  missing the diagnosis in patients at 
risk, and a relevant cost-benefit profile so as  avoid  unnecessary 
endoscopy and/or treatment of patients who would not benefit from 
therapy (i.e., high positive predictive value). In this scenario, we 
previously showed that the use of the platelet count/spleen diameter ratio 
for the noninvasive assessment of  EV seems to fulfill these requirements 
and is based on pathophysiological criteria as well.  
                    Furthermore, we validated the diagnostic  accuracy of this 
parameter in the follow-up of patients free from EV at screening 
endoscopy. Lastly, preliminary results obtained by other authors 
demonstrated that the diagnostic accuracy of the platelet count/spleen 
diameter ratio is maintained in subsets of patients with different etiologies 
of liver disease  and by applying different methodologies, thus suggesting 
the generalizability of the diagnostic method. 
                  In this prospective study, our aim is to assess the validity of 
using the platelet count/spleen diameter ratio for the  noninvasive  
diagnosis of  EV in patients with cirrhosis. In this study, we also aim to 
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assess  the validity of  this diagnostic tool in patients with various degrees 
of liver  function  impairment and in patients with various etiologies of 
liver disease. 
                       Splanchnic blood flow due to vasodilatation and greater 
resistance to the flow of blood through cirrhotic tissue causes portal 
hypertension.The major complication of portal hypertension is formation 
of oesophageal varices the prevalence of which is about 50%.About 33% 
of patients die from bleeding varices after its development.Incidence of 
bleeding from varices in the subsequent years especially in the 1st two 
years of detection increases by about thirty percentage.The mortality is 
high (about 40-70%) from the 1st  episode of bleeding.Thereafter the 
morbidity increases by five percent per year and the development of large 
varices is about 5-10% in the subsequent year and the rupture of those 
varices is more in the 2years following diagnosis.    
                      But the method has two problems viz…1.Invasiveness of 
the endoscopic procedure 2.Financial burden to the patient.These 
problems can be solved by using other biochemical,clinical and 
sonographic parameters which when put together have positive predictive 
value for noninvasive detection of varices.So that the invasive upper and 
lower G.I scopy will be done in only a group of patients thereby  
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 preventing needless intervention and  at the same time finding out the 
patients with varices.  
                     In order to reduce the workload on the endoscopic units and 
financial constrain to the patients, many non invasive procedures have 
been developed. One of the parameters related to portal hypertension is 
increased spleen size and thrombocytopenia which can be used as a better 
predictor to identify the engorgement of veins in portal hypertension. 
                     But shortcomings in this study incorporating platelet count 
as noninvasive predictor is that in patients with cirrhosis, the presence of 
thrombocytopenia may be due to 1.Reduced average platelet survival 
2.suppressed thrombopoitein levels 3.bone marrow suppressive effects of 
viruses and alcohol whereas spleenomegaly in cirrhosis is mainly due to 
disturbances in the vasculature correlated to portal hypertension. 
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  AIMS AND OBJECTIVES : 
  
• To assess the validity of  Platelet count / Splenic diameter ratio 
as a  non-invasive  predictor of Oesophageal Varices in 
Cirrhosis 
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 REVIEW OF LITERATURE 
                              Cirrhosis is an irreversible liver disease with definable 
pathological change and a spectrum of clinical features.The hallmark 
pathological events are 1.Chronic damage of the hepatocytes which is not 
reversible 2.fibrosis of the liver distorting the architecture 3.reactive 
nodular regeneration. 
                             Cirrhosis is defined “anatomically as a diffuse process 
with fibrosis and nodule formation”.The hall mark pathological feature  
chronic  extreme damage to the hepatocyte followed by replacement of 
normal liver tissue by fibrosis which is  extensive with nodule formation. 
This is  mainly due to necrosis of hepatocytes, loss of reticular network 
&regeneration of remaining liver tissue by nodules.Whatever may be 
etiology the end result is the same.. 
 Pathogenesis.  
                             The liver damage leads to activation of stellate cells in 
the space of disse. The stellate cells are activated cytokines which are 
primarily produced by hepatocytes, tissue macrophages(kupffer cells), 
lymphocytes and megakaryocytes. The cascade of events following 
stellate cell activation mainly by self stimulation leading to synthesis of 
platelet derived growth factor, transforming growth factor beta 1.these 
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stellate cells produce collagen matrix and substance that inhibit the break 
down of collagen. The substance that inhibit collagen break down are 
metalloproteinases 2 and 9 are inturn stimulated by TIMP 1and TIMP2, 
the other cytokines produced are T helper 2 lymphocytes – IL 6 and 13. 
            
                   
                 Similarly clinical manifestation often are due to alteration in 
the morphology and this correlates with severity of damage to the 
hepatocyte rather with the etiology of the liver disease. 
                 Distortion of functional hepatocyte may cause icterus, 
coagulation abnormalities,onasarca,vascular disturbances due to fibrosis 
(portal hypertension) and its complications – oesophageal varies  and 
splenomegaly.Both portal hypertension and hepatocellular damage cause 
ascites and hepatic encephalopathy. 
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                     Micronodular cirrhosis is  characterized by “ thick ,regular 
septa, with regenerating small nodules varying little in size, and 
involvement of every lobule.May represent impaired capacity for 
regrowth as in alcoholism, malnutrition ,old age and anaemia 
                     Macronodular  cirrhosis is characterized by “septae and 
nodules of variable sizes and by normal lobules in larger 
nodules.Previous collapse is shown by juxtaposition of three or more 
portal tracts in the fibrous scars. Regeneration is reflected by large cells 
with large nuclei and by cell plates of varying thickness.With time 
macronodular converts to micronodular” 
    
 
                         MACRONODULAR CIRRHOSIS. 
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                 EVOLUTION OF LIVER CELL DAMAGE. 
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                      Symptoms and Signs of Liver Cell Failure 
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            The clinical features of cirrhosis are….  
1.Liver enlargement (initially) 
2.Icterus  
3.Free fluid in abdomen (ascitis) 
4.Endocrine abnormalities – loss of erection and sparse pubic and axillary 
hair with gynaecomastia,atrophy of testis and impotence in malesand 
atrophy of breast secondary amenorrhea and menstrual disturbances in 
females. 
5. Palmar erythema,Spider naevi,Dupuytren contracture  
6.Hemorrhagic – bruises,purpura,menorrhagia & gum bleeding  
7.Portal hypertension – splenomegaly, G.I bleed.   
8.Hepatic encephalopathy and fetor hepatis. 
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   Aetiology of Cirrhosis :  
1.  Alcohol.  
2.  Viral hepatitis types B ± delta; type C.  
3.  Non alcoholic steatohepatitis. 
4.  Metabolic, e.g. haemochromatosis, Wilson's disease, α1 antitrypsin  
     deficiency, type IV glycogenosis, galactosaemia, congenital   
     tyrosinosis.  
5.  Prolonged cholestasis, intra-and extra-hepatic.  
6.  Hepatic venous outflow obstruction, e.g. venoocclusive disease, Budd-     
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     Chiari syndrome, constrictive pericarditis.  
7.  Disturbed immunity (autoimmune hepatitis).  
8.  Toxins and therapeutic agents, e.g. methotrexate, amiodarone.  
9.  Indian childhood cirrhosis.  
10.  Others: Malnutrition, infections, granulomatous lesions, cryptogenic  
     cirrhosis.  
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                              CHILD-PUGH CLASSIFICATION   
  
 
                     This classification is used to assess prognosis, especially to 
predict the mortality risk after shunt surgery.This is equally efficient 
similar to that of liver function test in ascessing the prognosis in patients 
waiting for liver transplantation. 
                     Now the system has been replaced by MELD score (Model 
For End  Stage Liver Disease) for risk stratification in Liver transplant 
recipients.It is a prospective scoring system useful in assessing the 
prognostic outcome in patients with liver disease and portal hypertension. 
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                       Parameters included in MELD score are prothrombin time 
expressed as international standardized ratio, serum bilirubin and serum 
creatinine. 
Prognosis: 
                      Cirrhosis as such has a poor prognosis.In case of one or 
more life threatening complications and in chronic decompensated 
disease, it has a very high death rate. About one fourth of patients have a 
survival  rate of five years when is there is functioning hepatotocytes. 
Only one fourth has ten year  survival. Prognosis mainly depends upon 
the etiology of cirrhosis especially when there is treatable conditions like  
alcoholics – have better prognosis. 
Portal Hypertension : 
                             The term portal hypertension was coined by Gilbert in 
1902. However, it was  not  until  1937  when Thompson  could  verify  
the  increase  in  portal  pressure directly  during laparotomy that portal 
hypertension was confirmed. It was way back in 1650 that Glisson  at  a  
dissection  in  London,  established the  portal  vein  as  the  vessel  by 
which blood was collected from the gastrointestinal tract and returned to 
the systemic  circulation.  As  early  as 1543,  Vesalius  drew  an  
anatomical  picture  of  the  portal  venous system.  
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                         The blood from the G.I tract mainly pancreas, spleen, gall 
bladder drain venous blood in to the portal vein, from there it enters the 
liver.  At the level of L2 superior mesenteric vein joins with splenic vein 
to form portal vein.  Portal venous system is a high flow, low pressure 
system. Portal pressure is related to Hepatic venous pressure gradient. 
HVPG is the difference in pressure between inferior vena cava and portal 
vein – it is <6mm Hg.  
 
 
       
                      
                              FORMATION OF PORTAL VEIN. 
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 PATHOPHYSIOLOGY OF PORTAL HYPERTENSION  
                                     Portal hypertension is  one  of  the  prime  
complications  of  cirrhosis.  Patients developing clinical features or 
complications of cirrhosis usually have portal venous pressures above 12 
mmHg.  
NORMAL PHYSIOLOGY  
                             The  movement  of  portal  blood  across  the  liver  is  
dependent  on  the  pressure gradient  between  the  portal  and  hepatic  
veins.  Hepatic venous pressure in part reflects the state of central venous 
filling pressure. Portal pressure is determined by the product of portal 
venous inflow and the vascular resistance to this flow:  
Portal pressure = portal flow x vascular resistance. 
                   Normally, the difference between portal venous pressure and 
hepatic venous pressure is never greater than 4mm Hg. A compliant liver 
acts as a blood reservoir to maintain a normal hepatic pressure gradient.  
                   When outflow pressure increases, an  increasing  number  of  
sinusoids  are  recruited  to  accommodate  these  changes.  Thus,  
elevations  of  hepatic  venous  pressures  do  not  result  in  similar  
increases  in  portal  pressure. 
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                     The main site of portal vascular resistance in humans 
appears to reside at the  level of the hepatic sinusoids. Portal  venous  
inflow  is  the  sum  of  the  flow  from  the  3  main  splanchnic  
tributaries.  The  splenic  vein  joins  the  inferior  mesenteric  vein  at  the  
level  of  the pancreatic  body  and  tail,  where  pancreatico duodenal  
vessels  also  enter.  Superior  mesenteric  venous  drainage  from  the  
small  and  proximal  large  intestine  joins  the  splenic vein at a site 
superior to the pancreatic  head, forming the portal vein trunk.  
                      The coronary vein drains the venous circulation of the 
lesser gastric curvature into the proximal portal vein. The gastroduodenal 
vein collects drainage from the area of the pancreatic head.  
                      Total  portal  venous  flow  in  a  normal  man  ranges  
between  600 and1200ml/min, as measured intra operatively and by 
Doppler  flowmetry. The  volume  of  portal  flow  is  regulated  by  the  
vascular  resistance  of  the  splanchnic arteries.  
                         Changes in portal inflow result from modifications in 
splanchnic  arteriolar  resistance, as seen with physiologic events such as 
a change in posture or in  the postprandial state. The increase in portal 
blood flow after a meal can be prevented  by  pre-administration  of  
somatostatin,  an  inhibitor of  the  release  of  several  gastrointestinal  
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hormones  that  may  mediate  the  arteriolar  vasodilatation  that  occurs  
after  feeding. 
                 Portal  venous  oxygen  content  decreases  after  a  meal  
because  of  increased intestinal arteriovenous extraction of oxygen.  
 
                   The sites of porto - systemic collaterals in patients with 
cirrhosis of liver.The most common of site of bleeding among patients 
with portal hypertension is from the gastro-esophageal varices. 
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 HEMODYNAMICS IN PORTAL HYPERTENSION  
Vascular Resistance  
                        Theoretically, a rise in portal pressure could stemfrom an 
increase in either  portal flow or vascular resistance. Under normal 
conditions, a rise in portal flow can  be  accommodated  by  the  
compliant  hepatic  sinusoidal bed  so  that  portal  pressure  increases  
only  in  extreme  conditions.  
                        For  example,  although  splenic  flow  increases markedly 
in the presence of massive splenomegaly, the critical threshold in the 
portal  flow-pressure relationship is not reached  and portal hypertension 
does not develop unless increased vascular resistance  is  also  present.  
                      This hemodynamic  combination  can  be  seen  in  
conditions  with  splenomegaly, such as  Felty's syndrome,  sarcoidosis, 
or lymphomas. An exception is  portal  hypertension  caused  by  a  high  
portal  flow  from  an  arterio- venous  fistula,  as  with  splenic  artery  
splenic  vein  communications,  where  the  flow-volume  relation  
exceeds a critical threshold.  
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                    The  genesis  of  portal  hypertension  involves  an  increase  
in  portal  vascular  resistance and is the basis for its classification. Insight 
into the location of vascular resistance in human cirrhosis has been 
provided by combined hepatic vein and portal pressure  measurements.  
                 Most  measurements  in  non-alcoholic  cirrhosis  show a 
higher  portal  venous  pressure  than  hepatic  venous  wedge  pressure, 
which is  an  estimate  of sinusoidal  pressure.  This  indicates  the  
presence  of a  pre  sinusoidal  component,  probably  related to 
inflammatory  activity  or  fibrotic changes in the portal triads.   
     In alcoholic  cirrhosis,  the  vascular  resistance  must  reside  at  
the  level  of  the  sinusoids because portal and hepatic venous wedge 
pressures are similar 
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 .  
                        The pathogenesis of the increased sinusoidal resistance in 
alcoholic cirrhosis is controversial.  The  concept  of  a  pathogenic  role  
for the  architectural  rearrangement  and development of fibrotic septa in 
cirrhosis has  been replaced by an emphasis on sinusoidal  events.  
Hepatocyte enlargement,  resulting  from  an  alcohol-induced  
accumulation of fat and protein, may compress the liver sinusoids and 
obstruct portal flow.  
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                 Studies of pre cirrhotic portal hypertension in baboons 
chronically fed with alcohol  have  suggested  that  the  degree  of  
perivenular  and  pericellular  fibrosis  induced  by  alcohol  correlates  
with  in  vivo  measurements  of  portal  pressure.   
                 This  further  implicates  the  hepatic  sinusoids  as  the  site  of  
increased  vascular  resistance  in  alcoholic  cirrhosis.  Capillarization  of  
these  low-resistance  channels,  with  loss  of  sinusoidal fenestrae, 
appearance of collagen in the space of Disse, and the presence of  
contractile myofibroblasts, may contribute to the development of 
increased sinusoidal resistance.  
                   A relation between hepatocyte size and intrahepatic pressure 
in alcoholic liver  disease  was  found  for  only  mild  to  moderate  
pressure  elevations,  although  the  accuracy of intrahepatic pressure 
measurements has  not been confirmed by others. In  non-alcoholic 
cirrhosis, a more complex relation exists between these parameters.  
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 Vascular disturbances in portal hypertension and sites of action of  portal  
pressure-reducing therapies. CC, contractilecell; EC, endothelial cell.  
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 PORTAL BLOOD FLOW AND THE SYSTEMIC CIRCULATION  
                             Two models have been proposed to explain the 
alternations of portal flow in  response to portal hypertension: 
                        1.Forward hypothesis 
                        2.Backward hypothesis 
"  
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                The  first is based on a rise in portal venous pressure  triggering 
a myogenic response that  reduces  splanchnic  arterial  inflow.  As  a  net  
result,  portal  pressure  values  drift  back  toward normal.  If the 
splanchnic circulation is considered as 2 organs in series (the  
gastrointestinal tree and the liver), the backward  flow hypothesis predicts 
that inflow  into the gastrointestinal tree would be reduced as  a result of 
this rise in portal venous  pressure. 
             Even when portal hypertension is fully established, the backward 
component contributes to its maintenance.  The  forward  flow  
hypothesis,  in  which  portal  venous inflow  is  increased,  is  based on 
observations in several experimental models and patients. 
            This paradoxical  increase  in  portal  venous  inflow  contributes  
to  the maintenance  of  portal  hypertension.  As a hemodynamic  
syndrome,  portal  hypertension  is  unique  in  exhibiting both increased 
inflow and increased resistance.  
             The  increase  in  portal  inflow  occurs  as  part  of  a  more  
generalised  hemodynamic  disturbance,  the  `hyperdynamic"  
circulation.  This  is  characterized  by  peripheral  vasodilatation,  a   
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 reduction  in  peripheral  vascular  resistance,  and  an  increase in plasma 
volume. As a result, cardiac output and heart rate increase.  
                     Decreases in splanchnic and muscular arterial resistance are 
the main factors contributing to the decrease in systemic vascular 
resistance. Variable effects are seen  on  the  renal  circulation,  in  which  
compensatory  mechanisms  such  as  renal sympathetic  nervous system  
activity,  renin-angiotensin,  and  circulating  catecholamines  may  
induce renal vasoconstriction in spite of a decreased peripheral vascular 
resistance.  
                       The  hyperdynamic  circulatory  state  is  seen  in  many  
forms  of  portal  hypertension. Humoral factors may be responsible for 
the development of peripheral vasodilatation.  Glucagon  levels  are  
elevated  in  the presence  of  portal  hypertension  and  porto  systemic  
shunts.  Other postulated humoral factors  include  prostacyclin,  
prostaglandins, bile salts and endotoxin mediated activation of nitric 
oxide.  
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Representative vasodilator and vasoconstrictor molecules implicated in  
              the vascular abnormalities in portal hypertension.   
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 PORTAL HYPERTENSION AS A HEMODYNAMIC SYNDROME  
Splanchnic hemodynamics  
     * Increased portal vascular resistance  
     * Increased portal venous inflow  
     * Portosystemic shunting  
Systemic hemodynamics  
         *  Arterial vasodilatation          
         *  Increased plasma volume.  
         *  Variable renal blood flow. 
        
                    A sequence of events that leads to the hyperdynamic state 
has been proposed. Although the primary pathophysiologic event is 
arterial vasodilation, a hyperdynamic  state would not develop unless 
sodium was retained by the kidney, a process mediated  by the activation 
of compensatory mechanisms triggered by the same vasodilatation. 
Plasma  volume  is  then  expanded,  which  triggers  a  further  decrease  
in  peripheral vascular resistance.  
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 Influences of Portal Hypertension on Other organs : 
                          Hypersplenism may occur in the absence of 
splenomegaly. Alterations of the splenic  microcirculation,  with  fibrotic  
changes  in  the  splenic  sinusoids,  favour  entrapment  of  red  cells,  
white  cells  (especially  polymorphonuclear  leukocytes),  and platelets. 
However, the bone marrow remains active and infection or bleeding 
seldom results  from  leukopenia  or  thrombocytopenia,  respectively.  In  
the  absence  of  other factors  that  affect  the  platelet  count  (alcohol,  
medications),  thrombocytopenia between  50,000  and  125,000  
platelets/mm  is  an  indicator  of  portal  hypertension  in cirrhosis.  
                          Hypoxemia, with an arterial partial pressure of oxygen 
between 60 and 80 mmHg, is a common finding in established portal 
hypertension. Administration of 100% oxygen  does  not  correct  the  
hypoxemia,  suggesting  that  functional  pulmonary arteriovenous  
shunting  is  the  basic  defect.  Anatomic  connections  have  been 
demonstrated  on  the  pleural  surface  and  termed  lung "spiders".  
Vasodilatation  of pulmonary  capillaries,  as  part  of  the  generalised  
process  of  systemic  vasodilatation may  increase  the  distance  for  
oxygen  diffusion  between  the  blood  and  alveolus, resulting in 
functional shunt. The degree of hypoxemia can be severe.  
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                             Pulmonary hypertension develops in a few patients, 
regardless of the etiology  of  portal  hypertension.  The  pathophysiology  
is  unclear.  Histologic  studies  do  not suggest  microscopic  pulmonary  
embolism  as  a  possibility.  Rather,  vasoactive substances  arising  from  
the  splanchnic  territory,  which  now  by  pass  the  liver,  may induce  
permanent  changes  in  the  pulmonary  vasculature.  Serotonin,  thought  
to  be elevated  in  these  patients,  is  of  particular  interest  as  it  has  
been  implicated  in  the pathogenesis of pulmonary hypertension 
associated with the carcinoid syndrome.  
CLASSIFICATION OF PORTAL HYPERTENSION  
                              A logical classification of portal hypertension is based 
on the site of increased resistance  to  portal  flow.  Five  main  groups  
can  be  delineated  according  to  pre sinusoidal,  sinusoidal,  or  post  
sinusoidal  block.  Pre  sinusoidal  and  post  sinusoidal portal  
hypertension  can  be  further  subdivided  into  intra-or  extrahepatic  
causes.  
Pre sinusoidal Pre hepatic :  
                               Presinusoidal extra hepatic portal hypertension is most 
commonly due to portal vein thrombosis. A blood clot in the portal vein 
can have several causes; however, a definitive diagnosis cannot be made 
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for many patients. Many of these idiopathic cases may represent  an  early  
manifestation  of  a  myeloproliferative  syndrome.  When  the colony-
forming  units  were  quantitated  after  bone  marrow  culture -  a  
diagnostic criterion  for  myeloproliferative  syndrome,  many  patients  
with  idiopathic  portal hypertension met criteria for the diagnosis of this 
hematologic disorder. Catheterization of the umbilical vein in newborns 
has been associated with the developmentof  omphalitis  with  secondary  
portal  vein  thrombosis.  Over the years, bridging collaterals develop 
toward the liver, resulting in a "cavernous" appearance of the portal vein. 
The prognosis is relatively good because these patients have normal liver 
function, variceal hemorrhage is better tolerated, and the incidence of 
bleeding decreases after the second decade.  
                       Disorders  of  the  coagulation  system  may  present  as  
portal  vein  thrombosis. These include congenital deficiencies of natural 
anticoagulants such as deficiency of antithrombin III, protein C, protein 
S, and plasminogen activator. An acquired lupus anticoagulant may also 
predispose patients to this thrombotic event.  
                        Diseases of the adjacent organs may also cause portal vein 
thrombi. Invasion  into the portal vein by carcinoma of the head of the 
pancreas or common bile duct denotes  inoperability;  carcinomas  of  the  
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pancreatic body  and  tail  affect  the  splenic vein. Cirrhosis has been 
viewed as predisposing to  portal vein thrombosis because of stasis.  
Pre sinusoidal portal hypertension  
  Extrahepatic  
•  Portal vein thrombosis  
  Intrahepatic  
•  Schistosomiasis (S.mansoni, S.japonica)  
•  Sarcoidosis  
•  Felty's syndrome  
•  Arsenic poisoning  
•  Idiopathic portal hypertension  
•  Congenital hepatic fibrosis  
•  Primary biliary cirrhosis( early stages)  
Sinusoidal portal hypertension  
•  Alcoholic cirrhosis  
•  Vitamin A intoxication  
•  Nodular regenerative hyperplasia 
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 Post sinusoidal portal hypertension  
  Intrahepatic : 
•  Veno-occulsive disease  
•  Senecio alkaloids  
•  Alcoholic hepatitis (venular sclerosis type)  
  Extrahepatic : 
•  Budd-Chiari syndrome  
•  Congenital web  
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                        Splenic vein thrombosis may give rise to gastric varices 
with hemorrhage. If the liver is normal, the gastric varices drain toward 
the liver through the coronary vein  and  esophageal  varices  may  be  
absent.  Chronic pancreatitis  and  many  of  the previously discerned 
disorders that cause portal vein thrombosis may also give rise to  this 
segmental abnormality. 
 Pre sinusoidal intrahepatic  
                        A  wide  range  of  disorders  are  included  in  this  
category,  but  portal  venule obstruction is the common link. It can occur 
as a result of vascular obliteration (non cirrhotic  portal  fibrosis)  or  as  a  
result  of  inflammatory  activity  in  the  portal  triad (early  stage  of  
primary  biliary  cirrhosis,  lymphoma)  that  impinges  on  the  portal 
venous system.   
                     Schistosomiasis is  the  most  common  entity  in  this  
group.  Eggs shed by  the  parasite into the splanchnic venous tributaries 
lodge in the portal vein radicles within the  liver.  A   granulomatous, 
fibrotic reaction develops around the  eggs  of  eitherSchistosoma 
mansoni or Schistosoma japonicum, obstructing portal venous flow. As a 
result, prominent hepatomegaly can be detected.  Splenomegaly  and  
portosystemic  collaterals  arise  as  a  consequence  of  portal  
hypertension.  With  progression  of  the disease,  cirrhotic  changes  may  
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develop,  resulting  in  an  additional  component  of sinusoidal resistance 
to portal flow.  
                       Non  cirrhotic  portal  fibrosis  (idiopathic  portal  
hypertension)  is  a  common  cause  of  portal  hypertension  in  Asia.  
Obliteration of small portal venules is  its  characteristic feature and liver 
function is preserved. Non cirrhotic portal fibrosis can  be  reproduced  in  
experimental  animals  by  injection  of  inactivated  Escherichia  coli  
into  the  portal  vein. This implies that  enteric  infection  is  a  possible  
cause.  Arsenic poisoning may also present with pre sinusoidal features.  
                       Inflammatory  infiltration  of  the  portal  triads  coexists  
with  splenomegaly  in  another  group  of  disorders.  Examples include  
Felty's  syndrome,  lymphoma,  and  sarcoidosis.  Several  chronic  
hepatic  disorders  have a  pre  sinusoidal  component  of  portal  
hypertension;  these  include  non  alcoholic  cirrhosis  and  primary  
biliary  cirrhosis. Congenital hepatic fibrosis may appear with portal 
hypertension as its initial manifestation.  
Sinusoidal                                                                                                                                                                                                                                                                               
Sinusoidal  portal  hypertension  is  the  characteristic  feature  of  
alcoholic  liver  disease.  Hepatitis  B-related  cirrhosis  has  also  been  
reported  to  involve  a  sinusoidal   resistance site.  Peri sinusoidal 
fibrosis with portal hypertension can be seen with vitamin A intoxication 
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and after renal transplantation. In the latter, azathioprine may be involved   
in its genesis. Endothelial damage can also be caused by other 
compounds with thiol groups. 
                  Classified within this group is nodular regenerative 
hyperplasia. The nodules in this entity are delineated not by fibrous tissue 
but by collapsed liver parenchymal cells. Mainly reported in patients with 
rheumatoid  arthritis, it has been described in a  wide  variety  of  
disorders,  including  myeloproliferative  disorders,  lymphoma,  
macroglobulinemia,  and  myeloma.  Occlusion  of  small  portal  venules  
may  be  the  primary disorder that leads to collapse of the reticulin 
framework and the appearance  of  nodules  not  surrounded  by  fibrous  
tissue.  Partial  nodular  transformation,  with  nodularity confined to the 
area of the hepatic hilum, may be a variant of this disorder.  
Postsinusoidal  
                       This can occur within or outside the liver. Most of these 
entities present with ascites as the main manifestation of portal 
hypertension. The causes include  
• Alcoholic hepatitis. 
• Veno occlusive insufficiency. 
• Hepatic vein thrombosis. 
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 The high pressure portal venous system is decompressed by extensive 
portosystemic communications resulting in formation of collaterals. 
SITES OF COLLATERALS: 
  1.Cardia of the  stomach.  
                                        Oesophageal and gastric varices (Left gastric 
vein,short gastric vein (portal system) join with intercostal, 
diaphragmatic, oesophageal and azygous veins of the caval system 
leading to oesophagogastric varices. 
2.At the anal canal 
                           Middle and inferior haemorrhoidal veins of the caval 
system joins with the superior haemorrhoidal vein of the portal system 
leading to rectal varices. 
3.Umbilicus.  
                         Remnants of the umbilical circulation of the foetus 
present in the falciform ligament form a large paraumbilical vein – Caput 
medusa. 
4.Other sites of anastomoses are retroperitoneal vein, lumbar vein, 
omental vein and veins over bare area of the liver. 
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SITES OF COLLATERALS FORMATION IN PORTAL 
HYPERTENSION –At each of these sites, tributaries of the portal venous 
system anastomose with tributaries of the caval system and provide a 
means to by pass the liver. 
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       INVESTIGATION OF THE PORTAL HYPERTENSIVE STATE  
Physical Examination  
                     A full clinical evaluation of patients with portal  
hypertension should include  elucidation  of  the  cause,  evaluation  of  
hepatic  function,  and  screening  for  complications. The physical 
examination may provide special clues to the differential diagnosis.  
                                                                             
                When patients present with variceal bleeding, cirrhosis should 
not be assumed and pre sinusoidal causes should be considered. However, 
when patients  with  portal  hypertension  also  exhibit  ascites,  a  pre  
sinusoidal  etiology  is  unlikely  unless  severe  hypoalbuminemia  alters  
the  relation  between  hydrostatic  and  oncotic pressure  in  the  
intestinal capillaries. Cirrhosis may eventually develop in   
schistosomiasis, and ascites may result from sinusoidal portal 
hypertension.                              
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Clinical features of Portal hypertension.  
• Collateral circulation and varices. 
• Ascites. 
• Congestive splenomegaly, hypersplenism. 
• Encephalopathy. 
• Congestive gastropathy.                            
               Liver size may offer clinical clues. A small liver in  the  
presence  of  portal  hypertension is suggestive of cirrhosis. The 
consistency of the liver edge can provide  additional  information,  
because  a  normal  edge  argues  against  a  sinusoidal  etiology.                                  
               The  detection  of  a  hepatic  bruit  may  suggest  primary  
carcinoma  presenting  with  variceal bleeding as its initial manifestation. 
A venous hum in the periumbilical area indicates high flow through a 
patent umbilical vein, excluding portal vein thrombosis as a cause.                                                
             The  appearance  of  a  common  ailment  such  as  hemorrhoids  
can  seldom  be  interpreted  as  an  initial  sign  of  portal  hypertension.  
However,  proctoscopic  examination may reveal additional signs, such as 
the presence of rectal varies.  
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IMAGING OF THE PORTAL VENOUS SYSTEM.  
1. Ultrasound:  
                           On examination when the portal vein > 11mm in 
diameter then it is reported to be dilated portal vein which is indicative of 
portal hypertension. 
 
                           It is useful in evaluating size and any altered echo 
pattern of the liver, free fluid in the abdomen, biliary tract obstruction. In 
normal individuals parenchyma of liver is homogenous and have 
consistent mid level echoes  whereas in cirrhosis with progressive fibrosis 
and nodularity there is diffuse attenuation in echo pattern that ranges 
from imperceptible coarsening of the echo to gross nodularity. 
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                     Cirrhotic liver differentiated from Non cirrhotic liver by 
using a ratio of caudate to right lobe width (C/RL) 
          C/RL = Transverse diameter of the Caudate lobe  divided by 
                       Transverse diameter of Right lobe.  
                       C/RL > 0.65 in cirrhosis. With this ratio cirrhosis can be 
diagnosed with 96% confidence, if it is < 0.65 cirrhosis is unlikely. 
Measurement of Spleen size: 
           Normal spleen size in adults - Males < 13 cm 
                                                          Females < 12cm. 
                   Usually measured by taking the measurement along the long 
axis of the spleen in the mid axillary line. Other methods are 
1. Splenic index (SI) = a * b 
a- transverse diameter(cm)  
b- vertical diameter(cm) 
2. Splenic volumetric index.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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 2.Doppler ultrasound  
                           Doppler US demonstrates the anatomy of the portal 
veins and hepatic artery.  Doppler  US  shows  spontaneous  hepato-fugal  
flow  in  portal,  splenic  and  superior  mesenteric veins in patients with 
cirrhosis. Variceal bleeding is more likely if the flow is hepato-petal.  
Colour  Doppler  is  a  good  way  of  demonstrating  portal  systemic  
shunts and the direction of flow in them. Duplex Doppler has-been used 
to measure portal blood flow. In cirrhosis, the portal vein velocity tends 
to fall and when less than 6cm/s portal hypertension is likely.  
            
  
                 Colour Doppler Ultraound of Porta Hepatis 
46 
 
3.C.T scan  
                      After contrast, portal vein patency can be established and 
esophageal varices may  be  shown  as  intraluminal  protrusions  
enhancing  after  contrast.  Gastric  varices  show as rounded structures, 
indistinguishable from  the gastric wall. In cirrhosis, the  venogram varies 
widely.  It may be completely normalor may show filling of large   
numbers of collateral vessels with gross distortionof the intra-hepatic 
pattern ('tree in winter appearance).  
4.X ray chest 
                A chest radiography may show an enlarged azygos vein 
appearing as a mass in the right hilar region or enlarged pulmonary 
arteries when pulmonary hypertension is associated with portal 
hypertension.  
               Fundico antral varices may be misinterpreted as mass lesions on 
upper gastrointestinal radiographs. Angiography of mesenteric vessels 
provides anatomical information and some functional data.   
 5. Splenoportography. 
                                      It offers  the  best  anatomic  detail  but  has  
seldom  been  used  because  of  concern  about  splenic  puncture.  
Small-gauge needles may be  safe  when  optimal  imaging  is  needed.  
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Venous phases  of  arterial  injections  can  be  enhanced with subtraction 
techniques, giving better anatomic detail.  
                 
MEASUREMENT OF PORTAL PRESSURE  
                    a. Direct  measurements  of  portal  venous  pressure  can  be  
obtained  by  direct  puncture  of  portal  tributaries  or  of  venules  
within the  liver. 
                 b. Splenic  pulp  pressure,  measured  at  the  time  of  
splenoportography,  may  accurately  reflect  portal  venous  pressure  but  
is  associated  with  risk  of  hemorrhage  from  the  puncture  site.  
               c. Catheterization of the umbilical vein, has been re-evaluated 
with use of the Doppler technique. 
             d. Percutaneous transhepatic measurements of portal pressure can 
be obtained at the time of portography. 
              e. Direct measurements in portal tributaries can also be made at 
the time of surgery.  All  these  techniques  require  an  additional  
measurement  of  hepatic  venous  pressure to evaluate the pressure 
gradient across the liver. Also, organ puncture can occur in patients with 
liver disease and coagulopathy. 
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           f. The alternative is to approach the liver by way of the hepatic  
vein.  During  hepatic  venous  catheterization,  the  catheter is maximally 
advanced and the vein occluded so that a sinusoidal pattern can  be  seen  
during  injection  of  dye. The pressure value  at  this  point  reflect  
hepatic  venous  wedge  pressure  under  normal  conditions.  Withdrawal   
of the catheter into the hepatic vein allows estimation of hepatic venous 
free pressure.  
              Use of the balloon catheter allows   measurements of free and 
wedge pressure from one position in the hepatic vein.  Accurate  
measurements  require  adequate  calibration  of  pressure  transducers  
because  the  range  of  normal  venous  pressure  values  is  narrow.  An 
accurate tracing can be identified by its normal respiratory variation and 
stable values; digital readout of pressure value   is unacceptable. 
Permanent records of such tracings should be   incorporated in the 
patient's chart.   
               When  the  etiology  of  portal  hypertension  is  unclear,  
pressure  measured  by hepatic venous catheterization can provide useful 
clinical information. A low hepatic venous pressure gradient in the 
presence of oesophageal varices, strongly argues for a pre   sinusoidal  
etiology.  This is   the hemodynamic  pattern  in  early  hepatic 
schistosomiasis. A high pressure gradient confirms the presence of 
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parenchymal liver disease, but diagnosing its etiology  requires  
additional  testing. 
             Percutaneous transhepatic measurements are useful in the 
diagnosis of the Budd - Chiari syndrome.  
            Measurements of pressure are important   when therapeutic 
measures are planned.  During surgery to relieve   portal  hypertension,  
evidence  of  adequate  decompression is provided by intraoperative 
pressure measurements. The success of transjugular  intrahepatic  
portosystemic  shunt  (TIPSS),  a  nonsurgical  technique  in  which a 
metallic stent is placed between the portal and hepatic veins, can be 
measured  by  the  reduction  of  portal  pressure.  When considering   
pharmacologic therapy with beta - adrenergic blockers, reduction of the 
portal venous pressure gradient to critical  levels decreases the occurrence 
of gastrointestinal haemorrhage. 
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MEASUREMENT OF VARICEAL PRESSURE  
                             Measurement of intravariceal pressure by puncture of 
esophagal varices before  sclerotherapy  has  been  reported.  Although 
initial  reports  suggested  identical  values  for intravariceal pressure and 
portal pressure, more accurate measurements indicated a  lower value for 
the former, because pressure is dissipated over a larger vascular bed.  
When  the  sclerotherapy  needle  is  introduced  into  the  varix,  it  can  
cross  the  varix  and  its  tip  lies  in  the  muscle  layer.  A  manometric  
capsule  has  been  used  to  measure  variceal  pressure  indirectly.  It  is  
mounted on  an  endoscope  and  positioned  over  a  variceal  column.  
The  pressure  that  obliterates  the  varix  is  equivalent  to  the  
intraluminal pressure and is recorded with its respiratory variation. This 
technique has  been used to measure variceal wall tension by multiplying 
the apparent diameter of  the varix by the recorded variceal pressure. 
With these parameters, wall tension was considerably higher in patients 
who had bled from varices than in non-bleeders.  
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Variceal Bleeding. 
 
                 
 
        It is the most life threatening complication of portal 
hypertension. Most  commonly bleeding arises from the oesophagogastric 
junction or from the cardia of the stomach. Bleeding  from the varices to 
be treated in acute setting by supportive measures followed by a 
definitive procedure. 
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 Factors predisposing to Bleeding:  
1. Large varices. 
2. Endoscopic variceal stigma(red spots, red 
stripes) 
3. Elevated portal pressure. 
4. Drugs like Nonsteroidal anti-inflammatory 
agents. 
5. Tense ascites. 
                          More than 2/3 will not bleed usually in the 1st  year of 
diagnosis. Half of the patients will lose their life with 1st episode of 
haemorrhage. Size of varices is directly proportional to the risk of 
bleeding assessed by endoscopy.The other predictor being the portal 
pressure that is HVPG > 6 mm Hg is more definitive.  
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 The best markers of bleeding are  
1. Endoscopic red wales, red stripes. 
2. Size of the varices. 
3. Function of hepatocytes assessed by 
childpughs grading.  
 
 
            Cirrhosis due to alcoholic etiology have more risk of 
bleeding. This is predicted by Doppler sonography based on portal vein 
diameter, size of the spleen and the presence of collaterals. 
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 Preventive methods for Bleeding: 
                                    1.Abstinence from alcohol. 
                                   2. Predisposing drugs to be avoided. 
Management includes  
1. Pharmacologic therapy. 
2. Endoscopic therapy. 
                           Acute variceal bleeding can be life threatening. This is 
defined clinically as systolic BP < 90 mm Hg, tachycardia, urine output < 
30ml/hr requiring blood transfusion. All patients with cirrhosis and GI 
bleed should receive broad spectrum antibiotics such as Ciprofloxacin. 
1. Replacement of blood, coagulation factors by fresh frozen 
plasma(coagulopathy). 
2. Monitor CVP, PCWP, urine output and mental status.Treatment of 
sequelae of portal hypertension especially variceal bleeding is 
titrated to reduce the hepatic venous pressure gradient(HVPG) to < 
12 mm Hg or 20% from the baseline.When the HVPG 
measurement is not feasible or available, reduction of resting heart  
rate by 25% - using beta blockers is reasonable. 
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3. Vasoconstrictors: 
a. Vasopressin. 
• 0.1to 0.5units/minute for 4to12hours  
• Then taper the dose and continue up to 
48hours. 
• It reduces blood flow in the portal venous 
system.  
• Side effects are coronary, bowel and 
peripheral ischaemia, AKI, hyponatraemia. 
•  Concurrent use of venodilators like 
nitroglycerine IV infusion, sublingual 
isosorbide dinitrate may enhance the 
effectiveness of vasopressin and reduce 
complications. 
b. Terlipressin. is a better alternative to vasopressin 
in the control of bleeding because of the beneficial 
effects in patients with hepatorenal syndrome. 
c. Somatostatin - direct splanchnic vasoconstrictor 
given as 250microgram iv stat followed by  
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d. infusion of 250microgram/hr for a period of 3to 5 
days. 
e. Octreotide- synthetic somatostatin analogue in a 
dose of 50microgram IV bolus followed by 
50microgram/hr. These drugs can be repeated if 
the bleeding is severe. 
f. Short acting nitrates via transdermal(10mg every 
12 hours), sublingual(0.6mg every 30 minutes) or 
IV(40-400mirogram/minute to maintain systolic 
BP > 90mm Hg) routes can be tried.They reduce 
the peripheral vasospastic effects of vasopressin 
and lower the portal pressure via direct 
vasodilatation of porto-systemic collaterals. 
g. Non selective beta blockers eg propranolol,   
nadolol are used prophylactically there by 
reducing the risk of first bleeding by 30%. They 
act by the unopposed alpha action by its 
vasoconstrictor effect. 
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  4.Sclerotherapy: 
 Mechanism- the sclerosant acts by causing vessel   
thrombosis due to inflammatory reaction of the 
adjacent tissues and thereby obliterating the varix. 
The agents used are sodium morrhuate(5%), sodium 
tetradecyl sulphate(1-2%) ,ethanolamine oleate(5%), 
polidacanol(1-3%). 
 
Complications: 
Local effects. Ulcers , bleeding, pain, odynophagia 
lacerations, oesophageal dysmotility. 
Regional. Perforation of oesophagus, inflammation of 
mediastinum, pleural effusion, dilatation of stomach. 
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Systemic. Septicaemia, spontaneous bacterial 
peritonitis, ventilation perfusion mismatch, ARDS, 
portal vein thrombosis, aspiration. 
       5.Banding:    
                              It is the procedure of choice in nonbleeding varices.                            
                              Rubber rings attached to a hollow cylinder in the tip  
                              of the scope are placed over the varices.       
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                               Banding leads to ischemia and necrosis of the mucosa  
                              and submucosa  by interrupting the flow followed  
                               by granulation tissue formation and other tissues are  
                               sloughed off  leaving a shallow ulcer in 2-3 weeks.   
                              Complications. Superficial ulceration, stricture,  
                              dysphagia. 
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6. Balloon tamponade  
                                   It is done by a triple or four lumen Sengstaken –  
                                   Blackemores tube with two balloons (gastric/  
                                        oesophageal). 
                                   
Complications: Aspiration pneumonitis, oesophageal 
rupture depending on the length of time the balloon is 
inflated. Hence it has to be deflated after 24 hours. If 
bleeding has stopped, the tube may be removed in 
another 24 hours 
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             Bleeding varices can be tackled mechanically or 
pharmacologically. Medical measures include drugs which reduce the 
portal pressure.Mechanical measures include compression of the varices 
by sengstaken Blakemore tube and sclerotherapy, banding. 
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7. Transjugular intrahepatic portosystemic stent shunting.(TIPSS) 
                          The stent is passed through the internal jugular vein 
under radio imaging. By angiography patency of portal vein is 
determined. Then the stent is kept between portal vein and hepatic vein 
which there by causes reduction of portal pressure. 
Complications include 
1. Bleeding associated with shunt occlusion or 
narrowing. 
2. Hepatic encephalopathy. This is managed by 
reducing the shunt diameter. 
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 8.Portosystemic shunt surgery: 
a. Non selective shunts to decompress entire portal  
  system. Eg side to side / end to end portocaval and  
  proximal splenorenal anastomosis.Portosystemic  
          
    encephalopathy common. 
                               b. Selective shunts that decompress only the varices  
                                  allowing blood flow to the liver.  
                                  Eg Distal splenorenal shunt. 
c. Splenectomy. – for isolated fundal varices caused  
    by splenic vein thrombosis. 
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                   The two major complications of portal hypertension are 
                                              1.Variceal Haemorrhage.  
                                              2.Ascites. 
                       Due to increase in the pressure of the portal venous system 
– it leads to formation of oesophagogastric varices, return of blood in to 
superior vena cava through azygos vein. The risk of bleeding from 
varices increases when HVPG > 12 mm Hg. 
Uses of  Endoscopy. 
                                 1.To detect the presence of varices and to asses high  
                                     risk features related to increased bleeding risk. 
                                2.To intervene therapeutically in case of acute  
                                   bleeding. 
The risk of bleeding can be assessed by  
                                1.Childs criteria. 
                                2.Presence of red wales. 
                                3.Size of varices. 
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                                       Oesophageal varices 
 
Grade 1  disappears completely with insufflation. 
Grade 2 Occlusion < 2/3 of the lumen. 
Grade 3 Complete occluson of the lumen. 
Another classification is  
1. Gastooesophageal varices (GOVs) 
GOV Type 1 – along the lesser curvature of  
the stomach. 
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 GOV Type 2 – along the greater curvature up 
to the fundus of the stomach 
2.Isolated gastric varices (IGV) 
Type 1 IGV – Variceal clustering along the 
fundus of the stomach. 
Type 2  IGV – Presence of varices in other 
parts of the stomach. 
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 ENDOSCOPIC SCREENING FOR OESOPHAGEAL VARICES  
                             Endoscopic grading of varices 
  Grade I: Small varices without luminal prolapse  
 
Grade  II :  Moderate-sized  varices  showing  luminal  prolapse  with  
minimal obscuring of the gastro-oesophageal junction.  
                       
68 
 
 Grade  III :  Large  varices  showing  luminal  prolapse  substantially 
obscuring the gastro oe sophageal junction 
                       .  
Grade  IV :  Very  large  varices  completely  obscuring  the  
gastroesophageal junction 
                     .  
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.                              MATERIALS AND METHODS 
 
STUDY POPULATION : 
                            The study will be conducted among  75 patients 
admitted in Medical ward,  Government  Rajaji  Hospital, Madurai with 
history and clinical features of Cirrhosis. 
INCLUSION CRITERIA: 
 Age > 18 years/ Males 
 Patients undergoing screening endoscopy for varices at the time of  
          diagnosis of cirrhosis. 
 Known cirrhotic patients who have never undergone screening  
          endoscopy for EV. 
EXCLUSION CRITERIA: 
       Patients with  
 Active upper G.I.bleeding 
 Previous history of endoscopic sclerosis / band ligation of  EV 
 Previous surgery for portal hypertension (stents) 
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 Previous history of Beta Blocker treatment / prophylaxis. 
 Inabilty to abstain from alcoholism 
ANTICIPATED OUTCOME 
                                        Platelet count/spleen diameter ratio is a 
predictable indicator for  noninvasive diagnosis of  esophageal varices in 
cirrhotic patients. 
DATA COLLECTION : 
                                      The following information will be collected for 
each patient:   age, gender, etiology of cirrhosis, biochemical parameters 
(aspartate aminotransferase [AST] , alanine  aminotransferase [ALT], 
total bilirubin, serum albumin, prothrombin activity (%), serum 
creatinine, platelet count, presence and degree of ascites and 
encephalopathy assessed according to ChildPugh  criteria, treatment with 
diuretics, and presence of contraindications to the use of nonselective β- 
blockers. The presence and size of EV will be determined and recorded 
for each patient. The size of  varices is subdivided into two classes—
small to screen and large to treat—according to the criteria  proposed at 
the Baveno I Consensus Conference. Small EV is defined as varices that 
flatten with  insufflation or minimally protrude into the esophageal 
lumen, while large EV is defined as varices  that protrude into the 
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esophageal lumen and touch each other (presence of confluence), or that 
fill  at least 50% of the esophageal lumen. This semiquantitative approach 
is chosen because it provides  better interobserver agreement as compared 
with quantitative grading. 
                          All patients will undergo ultrasonographic examination 
of the upper abdomen  including spleen bipolar diameter measurement. 
Ultrasonographic measurement of spleen bipolar  diameter is technically 
feasible in all patients. Both endoscopy and abdomen ultrasonography  
operators will be blinded to the others’ instrumental results and to the 
patients biochemical data. 
                            Platelet count/spleen diameter ratio is calculated in all 
patients as platelet  platelet count/spleen  diameter ratio will be evaluated 
in the whole cohort of patients as well as in two subanalyses carried  out 
by considering groups of patients with various degrees of liver function 
impairment (Child-Pugh  classes) and patients with various etiologies of 
liver disease. 
                           A previously designed profoma will be used to collect 
the demographic and  clinical details of the patients.A detailed history 
will be taken and a clinical examination will be  performed. 
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LABORATORY INVESTIGATIONS: 
Hb.                                  
Total Bilirubin:   Direct & Indirect                                                  
Total Protein    Albumin   Globulin  
SGOT(AST)  SGPT(ALT)      
Prothromin time  , Platelet count 
Peripheral blood smear.  
Ultrasonagram abdomen for splenic diameter  
 
DESIGN OF STUDY :  Prospective analytical study 
PERIOD OF STUDY : July 2013 to  August 2014 
COLLABORATING DEPARTMENTS : Department of General 
Medicine, Department of Medical  Gastroenterology, Deprtment of 
Radiology and Department of Biochemistry. 
ETHICAL CLEARANCE : Obtained 
CONSENT : Individual written and informed consent 
ANALYSIS : Statistical analysis- chi square 
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CONFLICT OF INTEREST :  NIL 
FINANCIAL SUPPORT :  NIL 
PARTICIPANTS :  Patients with history and clinical features of Cirrhosis 
admitted in Medical ward, Govt. Rajaji Hospital. 
STATISTICAL METHODS: 
        Descriptive  and  inferential  statistical  analysis  has  been  
carried  out  in  the present  study.  Results  on  continuous  measurements  
are  presented  on  Mean  ± SD  (Min-Max)  and  results  on  categorical  
measurements  are  presented  in  Number  (%).  Significance is assessed 
at 5 % level of significance.  
                 All the data was entered onto Microsoft excel sheet 2010 
version. The  statistical analysis was done using SPSS software. The 
statistical tools applied were mean, standard deviation, and chi – square 
test with Yates’ correction. The results were considered  very significant 
with p value < 0.01 and significant with  p value <0.05 Chi-square/ Fisher 
Exact test has been used to find the significance  of study parameters on 
categorical scale between two or more groups.  
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                                     Age distribution in our study. 
 
AGE 
NO OF 
CASES PERCENTAGE 
< 40 25 33.33 
41 - 45 14 18.67 
46 - 50 6 8.00 
> 50 30 40.00 
TOTAL 75 100 
 
 
 
 
 
 
 
75 
 
  
 
           
                 In our study majority of the patients were between 50-60 years. 
The youngest patient in our study was 31 years old and the oldest was 58 
years. 
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Sex distribution in our study. 
 
 
SEX 
NO OF 
CASES PERCENTAGE 
MALE 67 89.33 
FEMALE 8 10.67 
TOTAL 75 100.00 
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Comment : 
                    In our study males constituted >89% and females constituted 
10.67%. In our population males predominated the study.  
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                         Distribution of alcoholism in our study 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO OF 
CASES PERCENTAGE 
ALCOHOLIC 67 89.33 
NON-ALCOHOLIC 8 10.67 
TOTAL 75 100.00 
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Comment :  
                      In our study out of 75 patients, 67 patients gave a history of 
intake of alcohol > 180 ml/day. The remaining gave a history of blood 
transfusion. Thus alcoholics constitute >89.22% and blood transfusion 
constitutes 10.67%.  
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                          Hemoglobin distribution in our study 
 
 
 
Hb 
NO. OF 
CASES PERCENTAGE 
< 11.0 37 49.33 
> 11.0 38 50.67 
Total 75 100 
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Comment : 
                          In our study 37 patients had  Hemoglobin < 11gm%.This  
constitutes 49.33%  of the population and patients with Hb>11gm% 
constitutes 50.67% of the population. Chronic liver disease  causes 
anaemia of chronic disease due to direct suppression of bone marrow.  
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          Distribution of Serum Bilirubin among patients in our study 
 
 
 
 
 
 
 
 
 
 
 
 
SR.BILLRUBIN NO OF 
CASES PERCENTAGE 
1 TO 2 27 36.00 
2.1 TO 3 42 56.00 
3.1 TO 4 6 8.00 
TOTAL 75 100.00 
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Comment.: 
                     In our study, 42 patients had serum bilirubin between 2.1-
3mg/dl. Majority of patients with cirrhosis presented with jaundice. 
 
 
 
27 
42 
6 
0
5
10
15
20
25
30
35
40
45
1 TO 2 2.1 TO 3 3.1 TO 4
SR. BILIRUBIN 
84 
 
  
                         Serum Albumin distribution in our study 
 
 
ALBUMIN 
NO OF 
CASES PERCENTAGE 
< 3.0 gm 57 76.00 
> 3.1 gm 18 24.00 
TOTAL 75 100.00 
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Comment :  
                     In our study out of 75 patient, 57patients  presented with 
serum bilirubin of <3gm% that is it constitutes 76%. In chronic liver 
disease patient there is Albumin Globulin ratio reversal since liver is the 
major site of albumin production whereas the gamma globulin production 
occurs in the reticuloendothelial system. 
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      Correlation of Spleen diameter with oesophageal varices 
 
SPLEEN 
DIAMETER(mm) 
OGV 
+ve OGV -ve   
<  150 6 13 
>  150 44 12 
TOTAL 50 25 
 
 
         Chi square test was applied. Degree of freedom is 1. 
          P value < 0.012.This is statistically significant. 
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Comment.: 
                     In our study 44 patients with  spleen diameter > 150 mm 
developed oesophageal varices constituting 88% of the study with a                            
P value of< 0.012 ,which is  significant but it is less significant  than the 
association of platelet spleen diameter ratio with presence of OGV. 
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              Correlation of Platelet count with oesophageal varices. 
 
 
PLATLET COUNT OGV +ve OGV –ve 
< 125000 43 7 
> 125000 7 18 
Total 50 25 
 
 
Chi square test was applied. Degree of freedom is 1. 
P Value < 0.027.This is statistically significant. 
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Comment : 
                      In our study out of 75 patients 43 patients with platelet 
count > 125000 developed oesophageal varices constituting 86%.The  P 
value is < 0.027 which is significant but  this is less than that of the 
PC/SD ratio association with oesophageal varices. 
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Correlation of Platelet count Spleen diameter ratio with oesophageal 
varices. 
 
 
RATIO Positive Negative 
< 909 48 6 
> 909 2 19 
TOTAL 50 25 
 
 
Chi square test was applied. Degree of freedom is 1. 
The p value was found to be <0.007.This is statistically significant. 
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Comments. 
                     In our study out of 75 patients, 50 patients developed 
oesophageal varices. Out of 50 patients, 48 had PC/SC ratio of < 909 
which has a signicant P value < 0.007 with sensitivity of 96% and 
specificity of 90.48%. 
                   The positive predictive value of the study is 88.8% and the 
negative predictive value is 90.4%. 
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                                          DISCUSSION 
                        About 1/3rd of patients with chronic decompensated liver 
disease,  face the  life threatening complication of UGI bleed. The risk of 
bleeding from varices  increases in the subsequent years after diagnosis 
and is an important cause of mortality . This complication can be 
effectively managed prophylactically by nonselective beta blockers. 
Hence it emphasises the need for  a good screening procedure to prevent 
the complications. 
                    Many studies were conducted based on platelet count- spleen 
diameter ratio as a non invasive predictor of oesophageal varices in 
patients with cirrhosis. This study reduces the social and financial burden 
to the patient and this also improves the compliance of patients. 
                 In this study 75 patients of chronic liver disease were chosen 
based  on clinical, biochemical and ultrasonographic features, irrespective 
of etiology of  the disease. Then the patients were subjected to 
biochemical investigations like Hb%, serum bilirubin, serum proteins, 
serum albumin, SGOT, SGPT, prothrombin time, ultrasonogram  for 
diagnosis of cirrhosis.  
    In the first part of the study , platelet count and measurement of 
spleen by measuring the long axis of the spleen sonographically was done 
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in all the patients. In the second part of the study, patients were subjected 
to upper GI endoscopy to look for the presence of varices. 
               Patients with a prior history of variceal bleeding or prior 
documented varices were excluded from the study. Patients on beta 
blocker prophylaxis were also excluded from the study. 
   The use of this combined parameter is of interest and this 
hypothesis is evidenced by clinical and other biochemical parameters. 
Thrombocytopenia in cirrhosis is multifactorial it may be due to 
decreased platelet survival, impaired production of thrombopoietin or 
destruction, increased splenic sequestration due to hypersplenism. This 
led to the concept of taking spleen diameter hence thrombocytopenia can 
be attributed to hypersplenism. 
                   The use of this ratio normalises the platelet count to splenic 
sequestration since platelet count alone can be misleading and cannot be 
solely attributed to portal hypertension. 
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  AGE OF STUDY POPULATION 
  Incidence of cirrhosis was maximum in the age group > 50 years. 
Mean age was 45.94 with a standard deviation of 8.4.The youngest 
patient in our study was 31 years and oldest was 58 year. 
 
GENDER DISTRIBUTION 
Out of the 75 patients of whom 68 were males and 8 were females. 
Males constituted 89% of the study population. Males predominated our 
study. 
            In our study the majority of the patients presented with complaints 
of  jaundice, abdominal distension. Other symptoms were swelling of 
legs, easy fatiguiability. 
ALCOHOLISM 
            Among 75 patients studied  88% of the patients were found to be 
alcoholics. History of blood transfusion was seen in 12% of patients.  
PLATELET COUNT 
                         Majority of the patients had a platelet count between 
85,000 to 1,25,000/cubic mm .The mean platelet count in our study was  
121360+_17315. The P value is of <0.027 though it is significant as 
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single value, the significance is less when compared to combined 
parameter. 
SPLENIC DIAMETER 
          Spleen diameter in our patients ranged from 140 – 180 mm. The 
mean spleen diameter is 157+_12.89. The P value is < 0.012 it is less 
significant than PC/SD ratio. 
PC/SD Ratio and oesophageal varices. 
Among the 75 patients, a total of  50 patients had esophageal 
varices on upper gastrointestinal endoscopy. Out of these, 48 patients had 
a platelet count/splenic diameter <909. The remaining 2 patients had a 
ratio of >909. 
               A total of 54 patients in the study had a ratio of <909 in the 
study. Varices were absent in 4 of them. The mean platelet count spleen 
diameter ratio of patients with out varices was 961.98 and the mean 
platelet count spleen diameter ratio of patients with varices was 689.62.  
Hence, using a ratio of 909 as cutoff, 96% of patients with varices were 
detected (sensitivity-96% and specificity-90.48%). The P value <o.oo7 
which is more significant than using a single parameter. The positive 
predictive value is 88.% and the negative predictive value is 90.4%. 
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                This is in accordance with the  study conducted by Gianni, 
Botta, Borro in which they evaluated prognostic and diagnostic accuracy 
of the platelet/spleen diameter ratio for the presence of varices. They 
included 106 cirrhotic patients with out varices at initial screening 
endoscopy and endoscopy was carried in these patients. These patients 
were followed by excluding who lost their follow up or died before 
undergoing control endoscopy. During follow up 27 patients( 40%) 
developed varices. Patients with higher PC/SD RATIO ( p<0.0001) as 
well as ratio > 909 were less likely to develop varices (p< 0.0005). At 
follow up, PC/SD ratio < or = 909 had 100% negative predictive value 
and 84% efficiency in identifying the presence of varices.  
               Another  study by Ying L1 et al was done to assess the 
performance of PC/SD ratio for diagnosis oesophageal varices.This was a 
meta analyais. The Fagan plot was used for calculating PC/SD for 
oesophageal varices. If PC/SD ratio was below 909 for varices, post test 
probability was 87%, while if PC/SD RATIO was at or over 909, the post 
test probability was only 9%. This study decreases the need for invasive 
procedure in chronic liver disease patients. 
              This is in accordance with the study done in DHQ Hospital by 
Khalld amln et al 95 patients are included secondary to Hepatitis C virus. 
47 patients (49.5%) were male and 48 (50.5%) were females. The mean 
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age of the patients was 57 years. The maximum patients were 38% and 
were in the  range of 51-60 years. The mean platelet count to spleen 
diameter ratio of all the patients was 834.48. The mean platelet count to 
spleen diameter ratio of patients without varices was 1162.41and those 
with varices was 704.28. Considering > 909 as normal as a predictor of 
oesophageal varices the specificity(true negative case) is 81.48%. 
Positive predictive value is 92.42% and negative predictive value was 
found to be 75.86%. 
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 Limitations of the study 
• Sample size is small. 
• The study would be more precise if the 
etiological work up is done for all patients. 
• Grading of varices cannot be done with the cut 
off value 909 for all patients.  
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SUMMARY 
                        In  our  study,  fifty  patients  with  newly  diagnosed  
cirrhosis  without  prior  history of gastrointestinal bleeding were 
subjected to clinical evaluation. All patients  underwent  biochemical  
tests,  like  liver  function  tests,  complete  blood  counts,  renal  function 
tests,  prothrombin  time,  ultrasonography  of  the  abdomen  to  confirm  
the  presence of cirrhosis and to record the spleen bipolar diameter and 
ascites. 
                  Upper GI  endoscopy  was  done  in  all  patients  to  confirm  
the  presence  of  varices  and  also  to  grade  them.  We  tried  to  
identify  non-invasive  parameters  for  predicting  esophageal  varices in 
Cirrhotic patients. We assessed the role of Platelet count/Splenic diameter  
ratio  for  predicting  esophageal  varices  in  cirrhotic  patients.  Presence  
of  varices  increases  as  patients  progress  to  decompensated  liver  
disease.  (Child  Pugh  grade  B & C).  Decrease in the platelet count is 
associated with higher grades of esophageal  varices in patients with 
cirrhosis of liver. Ultrasound measurement of Spleen bipolar  diameter 
also predict the presence of higher gradesof esophageal varices .  When  a  
cut  off  value  of  Platelet  count/  splenic  diameter  ratio  of  ≤ 909was  
applied  in  order  to  take  in  to  consideration  the  decrease  in  platelet  
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count  due  to  hypersplenism;  it  was  found  to  be  a  good  predictor  of  
presence  and  grade  of  esophageal varices . The sensitivity of PC/SD 
Ratio of ≤909 in predicting presence of  esophageal varices was 96% with 
its positive predictive value was .  The study found that there is 
significant sensitivity and positive predictive value  enough to show the 
presence of varices in the study group. The  use  of  Platelet  count  and  
Platelet  count/  Splenic  diameter  ratio  in  appropriate subgroups of 
cirrhotic patients for screening and follow up of esophageal  varices can 
substantially reduce the cost of healthcare and discomfort for patients as  
well as reduce burden on Endoscopy units.  
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CONCLUSION 
             Higher  grades  of  esophageal  varices  exists  with  lower  
platelet  and  larger  spleen size. Lower the platelet count spleen size 
ratio, higher the incidence of varices  and higher the grades.   
• Inverse  correlation exists with platelet count and  ratio of platelet 
count  with  spleen diameter in relation to presence and grading of 
esophageal varices   
• Platelet  count  and  platelet  count  with  spleen  size  ratio  can  be  
used  as  non  invasive  markers  of  presence  of  esophageal  
varices   
• From  our  study  we  conclude  that  presence  of  a  lower  PC/SD 
ratio determine the presence of  varices and can hence identify  the  
subset  of  patients  who  require  endoscopy  for  the  prophylactic  
management  of  esophageal  varices.   
• This can help in decreasing the burden  on  the  endoscopy  units 
and can help  avoid  unnecessary screening endoscopies  
•   Apart  from  being  noninvasive,  platelet  count,  spleen  bipolar  
diameter  and  the  PC/SD  ratio  is  a  relatively  inexpensive  test. 
as  platelet  counts  and  abdominal ultrasounds would be obtained 
on all cirrhotic patients routinely as part of  their clinical workup. 
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                                                PROFORMA 
Case no :      
Name:                                               Age and Sex :                     IP no. : 
Occupation :                                     Address : 
 
Date of Admission :                         Date of Discharge : 
Chief Complaints : 
                              Yellowish discoloration of urine and eyes 
                               Abdominal Distension 
                               Swelling of legs/scrotum/labium 
                               Decreased urine output 
                               Hemetemesis 
                               Malena 
                               Breathlessness 
                               Loss of appetite / Vomiting 
                               Altered behaviour/involuntary movements 
 
 
                               Rashes/ other skin lesions 
                               Constipation 
Past History :  
            History of  Diabetes / Hypertension / CAD / Thyroid disorder /  
            CAD /  Chronic lung disease 
            History of  Drug intake / Blood transfusion 
Personal History : Smoker / Alcoholic – Amount per day & how long 
Clinical Examination  
General examination: 
Vitals : PR-                      BP-                    RR-               Urine Output:         
Consciousness / Oreintation / Pallor / Icterus / Cyanosis / Clubbing / 
Pedal edema / Axillary & pubic hair / Parotid enlargement / Testicular 
atrophy / Flapping Tremor / KF Ring / Constructional Apraxia       
Abdomen : 
Other systems : 
CVS-                                             RS-                                           CNS- 
 
 
 
 CLINICAL DIAGNOSIS : 
Investigations: 
Hb           TC            DC             Urine : Albumin          Sugar      Deposits   
Blood Sugar:               Fasting             Postprandial                                
Blood Urea :                                        Serum Creatinine: 
Total Bilirubin:           Direct              Indirect                                                  
Total Protein               Albumin          Globulin  
SGOT(AST)               SGPT(ALT)      
Prothromin time          Platelet count  
Peripheral blood smear. 
Ultrasonagram abdomen for splenic diameter: 
Course of patient in hospital : 
Treatment given : 
Outcome : 
 
 
 
S.
N
O
 
AG
E 
SE
X 
SI
G
N
 O
F 
LI
VE
R
 
C
EL
L 
FA
IL
U
R
E 
AL
C
O
H
O
LI
C
 
BL
O
O
D
 
TR
AN
SF
U
SI
O
N
 
H
B 
SR
.B
IL
LR
U
BI
N
 
SR
.P
R
O
TE
IN
 
AL
BU
M
IN
 
PT
 
PL
AT
LE
T 
C
O
U
N
T 
SP
LE
E 
D
IA
M
TR
E(
m
m
) 
R
AT
IO
 
O
 G
 V
 
1 45 M + + - 10 1.7 6.5 2.5 19 110000 140 785.71  +   
2 39 M + + - 12 2.1 7 2.1 23 105000 156 673.07  +   
3 38 M + + - 13.1 1.4 6.2 2.3 19 93000 153 607.84  +   
4 40 M + - + 12.3 2.5 6.1 2.5 23 114000 167 682.63  +   
5 49 M + + - 11.5 1.8 6.7 2.8 19 126000 158 797.46 - 
6 38 M + + - 9.2 3.2 6.5 2.1 21 110000 165 666.66  +   
7 45 M + + - 10.1 1.8 6.1 2.8 21 140000 141 992.9 + 
8 29 M + - + 13.1 2.5 6.4 2.9 19 104000 155 670.96  +   
9 52 M + + - 11.5 1.8 6.1 2.5 21 98000 160 612.5  +   
10 32 M + + - 12 2.3 6.4 3.1 17 151000 136 1118.85 - 
11 38 M + + - 12.1 2.5 7 3.5 19 107000 170 629.41  +   
12 38 M + + - 12.5 2.1 6.1 2.8 16 122000 164 743.9  +   
13 52 M + + - 11.5 2.8 6.2 2.4 23 133000 145 917.24 + 
14 51 M + + - 13.1 3.5 7 2.5 19 99000 145 682.75  +   
15 44 M + + - 12 3.6 6.5 1.8 19 116000 165 703.03  +   
16 46 M + + - 12.5 2.5 6.1 2.5 18 104000 172 604.65  +   
17 53 M + + - 12.1 2.5 6.1 2.4 19 137000 136 1007.32 - 
18 49 M + + - 11.5 2.1 5.8 2.9 25 145000 138 1050.72 - 
19 38 M + + - 11.5 2.3 5.9 3.1 19 114000 162 712.5  +  
20 33 M + + - 12 1.3 5.5 2.5 23 122000 171 713.45  +  
21 39 M + + - 13 2.2 6.5 2.2 19 101000 154 655.84  +   
22 31 M + + - 11.5 2.2 6.5 2.2 19 101000 154 655.84  +   
23 37 M + + - 12.5 2.5 5.8 3.5 24 94000 181 519.33  +   
24 42 M + + - 11.5 1.6 5.5 3.1 27 92000 173 531.79  +   
25 51 M + + - 10.5 2.6 6.3 2.1 21 153000 145 1055.17  - 
26 53 M + + - 10 2.1 6.1 2.8 18 113000 161 701.86  +   
27 56 F + - + 10.6 1.9 6.1 3.1 17 142000 137 1036.44  - 
28 36 M + + - 10.5 1.83 6.8 3.3 21 107000 155 648.48  +   
29 33 M + + - 11.5 2.6 5.8 2.5 19 121000 165 780.64  +   
30 57 F + + - 9.8 2.3 6.3 2.1 16 137000 128 1070.38 - 
 
 
31 56 F + + - 10.5 1.9 6.4 2.1 19 131000 134 977.61 - 
32 37 M + + - 11 1.8 6.5 2.1 27 113000 152 734.4  +   
33 57 M + - + 10.5 2.1 6.1 2.5 21 104000 173 601.15  +   
34 43 M + - + 11 2.8 5.8 2.3 23 93000 164 567.07  +   
35 45 M + + - 10.3 3.1 5.9 3.1 25 128000 143 895.1 - 
36 51 M + + - 11.2 2.1 6.6 2.7 23 167000 153 1024.53  - 
37 49 F + - - 10.5 1.9 6.3 2.1 21 147000 138 1065.21 - 
38 45 M + + - 10.3 3.1 5.9 3.1 25 121000 165 612.12  +   
39 31 M + + - 11 1.8 6.1 2.5 26 118000 173 641.61  +   
40 57 M + + - 10.5 2.4 6.1 2.5 24 121000 172 703.48  +  
41 38 M + + - 10.1 1.6 6.3 3.1 21 118000 165 715.15  +   
42 56 F + + - 9.8 1.7 6.4 2.6 19 137000 155 1014.81 - 
43 59 F + - - 10.1 2.9 6.5 2.5 23 129000 135 955.55 - 
44 36 M + + + 11.1 1.3 6.1 2.5 19 125000 171 730.99  +   
45 42 M + + - 12.3 1.5 5.9 2.4 17 111000 165 672.72  +   
46 57 M + + - 11.4 2.1 7 2.3 21 103000 161 639.75  +   
47 39 M + + - 10.5 2.9 6.5 2.1 23 110000 173 635.83  +   
48 42 M + + - 12.1 2.5 6.6 2.1 26 122000 173 705.2  +   
49 59 M + + - 9.5 2.6 6.3 2.7 20 131000 125 1048 - 
50 56 M + + - 10.6 2.8 5.9 3.1 19 121000 155 780.64 - 
51 47 F + + + 12.2 2.1 6.4 2.7 22 123000 163 754  +   
52 57 M + + - 11.5 1.9 6.6 2.5 25 108000 155 696.77  +   
53 43 M + + - 11.1 1.8 6.5 2.1 24 125000 173 722.54  +   
54 38 M + + - 11.5 2.6 6.6 2.6 19 157000 147 1027.21 - 
55 39 M + + - 11.5 2.9 6.3 2.3 21 160000 172 930.23 - 
56 52 M + + - 9.2 2.5 6.2 2.5 21 110000 163 674.84  +   
57 53 M + + - 10.1 1.8 6.1 2.1 23 127000 151 841.05 - 
58 51 M + + - 10.5 1.7 6.5 3.9 19 99000 162 611.11  +   
59 39 M + + - 11.5 2.9 6.4 2.3 21 155000 165 939.39 - 
60 52 M + + - 10.5 2.1 6.8 2.1 19 124000 152 815.78 - 
61 41 M + + - 12 3.1 6.7 2.4 15 108000 177 610.16  +   
62 57 F + - - 10.5 2.8 6.6 2.2 23 110000 163 674.84  +   
63 39 M + + - 10.9 2.4 5.9 2.6 21 118000 179 659.21  +   
64 41 M + + - 10.7 2.7 6.1 2.5 19 149000 153 973.85 - 
65 46 M + + - 11.3 1.7 6.3 2.3 19 137000 149 919.68 - 
 
 
  
 
 
 
66 41 M + + - 9.5 1.9 6.3 2.1 27 121000 149 812.08 - 
67 57 M + + - 10.1 2.1 6.1 3.1 29 112000 173 647.39  +   
68 42 M + + - 11.1 1.6 6.5 3.1 20 120000 165 727.27  +   
69 55 M + + - 9.1 2.1 6.2 3.1 25 124000 152 815.78  +   
70 57 M + + - 10.5 1.9 6.5 3.5 19 143000 151 947.01 - 
71 57 M + + - 11.1 2.1 6.4 3.1 19 139000 147 945.57 - 
72 55 M + + - 9.1 2.1 6.2 3.1 25 126000 152 828.94  +   
73 52 M + + - 10.5 1.6 6.1 2.8 25 111000 151 735.09  +   
74 57 M + + - 10.1 2.1 6.7 2.4 29 125000 151 827.81  +   
75 39 M + + - 11.1 1.9 6.9 2.6 21 110000 171 643.27  +   
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